The Hospiten Group is developing a clinical trial led by the specialist in Urology and head of the Pelvic Floor Unit, Guillermo Conde, to treat women affected by overactive bladder, a very frequent pathology that especially affects women from the age of 50.
This novel line of research is directed from Hospiten Rambla together with the University of Las Palmas de Gran Canaria, within the framework of the Chair of Medical Technologies. Its objective is to investigate the use of non-invasive superficial neurostimulation in a pathology that alters the functioning of the urinary system in a significant percentage of the population called "overactive bladder".
Dr. Conde, principal investigator of the trial, explains that "we are currently in the patient recruitment phase." The two centers where this treatment is being carried out are Hospiten Rambla and the Pelvic Floor Unit of the Gynecology Service of the C.H.U. Insular-Materno Infantil of Las Palmas de Gran Canaria. The first results will be obtained at the end of 2020 and we hope to communicate them to the scientific community next year. The clinical trial is open in the patient inclusion period and women affected by this type of pathology can participate by contacting Hospiten Rambla or through the Hospiten website .
Overactive bladder is a health problem that affects approximately 30% of women over 40 years of age in Spain. This pathology progressively generates urinary incontinence and urge incontinence, considerably limiting the quality of life by affecting work and social life. Many women mistakenly believe that this problem is part of aging and suffer from it without consulting their doctor.
Non-invasive superficial neurostimulation is a novel, harmless therapeutic system that has been used successfully in elite athletes, improving their sports performance. Among the beneficial effects, it has been found to regulate organic functions dependent on the autonomic nervous system, such as the functioning of the urinary system or the sleep pattern. These aspects have been the origin of this research.
Dr. Conde explains that when we want to apply a new therapy in medicine, this type of study called clinical trials is designed. They are carried out under international quality standards where patients are strictly supervised and all the effects and benefits of the treatment are thoroughly analyzed. The initial pilot study that we carried out before designing this trial showed us very positive results without side effects, so we hope that this trial will objectively demonstrate benefits for our patients and consolidate this therapy.
On the occasion of International Clinical Trial Day, which is celebrated tomorrow, May 20, Dr. Conde affirms that Spain is an international reference in clinical research, since a third of the trials in Europe have the participation of Spanish centers.
